Dr. Fleming on imaging agent 18F-rhPSMA-7.3 and SPOTLIGHT trial in prostate cancer

Mark Fleming, MD, Virginia Oncology Associates (US Oncology Network), discusses the novel PET imaging agent 18F-rhPSMA-7.3 and findings with the agent in the phase 3 SPOTLIGHT trial. Results from the study presented by Fleming at the 2022 AUA Annual Meeting showed that PET imaging with 18F-rhPSMA-7.3 frequently led to post-scan disease upstaging compared with baseline conventional imaging in men with prostate cancer recurrence.